This case report highlights sorafenib as maintenance therapy postallogeneic hematopoietic stem cell transplantation (allo-HSCT) in a young patient with acute myeloid leukemia (AML) with FMS-like tirosine kinase-3 (FLT3)-internal tandem duplication (ITD) mutation. Given the high relapse risk in FLT3-ITD-positive AML, the tyrosine kinase inhibitor sorafenib was administered. Several studies have shown that sorafenib improves survival in younger AML patients when combined with chemotherapy, though side effects can limit use in older patients. Sorafenib is increasingly significant after allo-HSCT maintenance, offering a promising option for high-risk AML cases. In this case, the patient achieved long-term remission with minimal side effects.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/CAD.0000000000001672 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Exosomal miR-6126 as a novel therapeutic target for overcoming resistance of anti-cancer effect in hepatocellular carcinoma.
BMC Cancer
December 2024
Division of Life Sciences, College of Life Science and Bioengineering, Incheon National University, Incheon, 22012, Republic of Korea.
Background: Hepatocellular carcinoma (HCC) stands as the sixth most prevalent cancer globally, presenting a substantial health challenge, particularly due to late-stage diagnoses that limit treatment effectiveness. Sorafenib, a multi-kinase inhibitor, is the primary chemotherapeutic agent for advanced HCC, but it only extends survival by 2-3 months. However, drug resistance remains a major clinical challenge, necessitating the exploration of new molecular mechanisms, including the role of microRNAs (miRNAs) in sorafenib resistance.
View Article and Find Full Text PDFDGKH-mediated phosphatidic acid oncometabolism as a driver of self-renewal and therapy resistance in HCC.
Hepatology
November 2024
School of Biomedical Sciences, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.
Article Synopsis
- Hepatocellular carcinoma (HCC) has metabolic abnormalities that help cancer cells grow and resist treatment, making it vital to study new metabolic factors linked to these issues for better understanding and potential therapy advancements.
- An analysis of cancer data revealed that a particular gene module correlates with advanced HCC disease and the maintenance of cancer stem cells, leading to the identification of 361 deregulated genes, with diacylglycerol kinase eta (DGKH) being a key player in promoting aggressive cancer traits.
- DGKH's elevated levels in tumors make patients less responsive to treatments, and its action involves enhancing mTOR signaling through phosphatidic acid production; targeting DGKH may improve treatment outcomes
Sorafenib as maintenance therapy in FLT3+ acute myeloid leukemia post allogeneic transplantation: a case report.
Anticancer Drugs
February 2025
Pharmacy Service, Hospital Universitario Virgen de las Nieves.
This case report highlights sorafenib as maintenance therapy postallogeneic hematopoietic stem cell transplantation (allo-HSCT) in a young patient with acute myeloid leukemia (AML) with FMS-like tirosine kinase-3 (FLT3)-internal tandem duplication (ITD) mutation. Given the high relapse risk in FLT3-ITD-positive AML, the tyrosine kinase inhibitor sorafenib was administered. Several studies have shown that sorafenib improves survival in younger AML patients when combined with chemotherapy, though side effects can limit use in older patients.
View Article and Find Full Text PDFAutophagy and inflammasome activation are associated with poor response to FLT3 inhibitors in patients with FLT3-ITD acute myeloid leukemia.
Sci Rep
October 2024
Department of Medical Images, Hematology, and Oncology, Ribeirão Preto Medical School, University of São Paulo, 3900 Bandeirantes Avenue, Ribeirão Preto, São Paulo, 14040-900, Brazil.
Article Synopsis
- Acute myeloid leukemia (AML) is a complex disease with diverse clinical features and significant molecular challenges, particularly related to FLT3 mutations.
- Researchers investigated the interactions between autophagy and the inflammasome to understand how these pathways might impact FLT3 inhibitor effectiveness in treating AML.
- Their findings suggest that autophagy and inflammasome activation are linked to poor responses to FLT3 inhibitors, indicating a need for further study on these pathways to enhance treatment strategies.
Sorafenib maintenance after allogeneic stem cell transplantation in patients with FLT3+ AML receiving midostaurin during induction and consolidation: a retrospective analysis.
Front Oncol
September 2024
Bone Marrow Transplantation (BMT) Unit, AOR Villa Sofia-Vincenzo Cervello, Palermo, Italy.
Article Synopsis
- Acute myeloid leukemia (AML) relapse is a major cause of mortality following allogeneic stem cell transplants, but using Sorafenib for maintenance post-transplant has shown to lower relapse and death rates in FLT3+ AML patients.
- In a study with 29 adult FLT3m AML patients who received allo-SCT, Sorafenib was administered as maintenance therapy after their initial treatment with midostaurin and chemotherapy.
- Results indicated that 62% of patients received Sorafenib; those who did had significantly improved 2-year overall survival (94%) and lower relapse rates (11%) compared to the whole population (76% OS, 28% CIR).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!